Cambrex is a provider of products, services and technologies to accelerate the development and commercialization of small molecule therapeutics.
The company also offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals.
With the DKMA certification Cambrex said that it will now accelerate the European launch of Nicotine Replacement Therapy (NRT) products (chewing gums, lozenges and mini-lozenges).
Cambrex Zenara president Ashok Narasimhan said they are very pleased with the results of the DKMA inspection.